Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhishu Tongbian Granules is a Traditional Chinese Medicine (TCM) formulation developed by Jianmin Pharmaceutical Group for the treatment of pediatric functional constipation. The drug is specifically indicated for children presenting with the TCM pattern of internal accumulation of dry-heat (里实热证/积滞化热). The formulation is based on the traditional 'Zhishu' herbal pairing, which typically consists of *Fructus Aurantii Immaturus* (Zhishi) and *Rhizoma Atractylodis Macrocephalae* (Baizhu), intended to regulate gastrointestinal qi, strengthen the spleen, and facilitate bowel movements. As of 2025, the candidate is undergoing Phase III clinical evaluation in China to assess its efficacy and safety in pediatric patients compared to a low-concentration control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhishu Tongbian Granules.